Charles River Laboratories International, Inc. (NYSE:CRL) Receives $256.38 Average Target Price from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $254.50.

A number of analysts recently weighed in on CRL shares. Mizuho began coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price target for the company. TD Cowen dropped their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research note on Monday, May 13th. The Goldman Sachs Group initiated coverage on shares of Charles River Laboratories International in a report on Thursday, June 6th. They issued a “buy” rating and a $290.00 target price on the stock. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday. Finally, StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the sale, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of the company. VisionPoint Advisory Group LLC grew its position in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $41,000. Operose Advisors LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $42,000. Brown Brothers Harriman & Co. lifted its holdings in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $62,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $206.58 on Thursday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00. The stock has a market cap of $10.64 billion, a PE ratio of 24.30, a price-to-earnings-growth ratio of 1.96 and a beta of 1.40. The firm has a fifty day moving average price of $220.16 and a 200 day moving average price of $232.63.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 11 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).